HK1137756A1 - 取代二氫吡唑啉酮和它們作爲 -脯氨酰- -羥化酶抑制劑的用途 - Google Patents

取代二氫吡唑啉酮和它們作爲 -脯氨酰- -羥化酶抑制劑的用途

Info

Publication number
HK1137756A1
HK1137756A1 HK10102676.5A HK10102676A HK1137756A1 HK 1137756 A1 HK1137756 A1 HK 1137756A1 HK 10102676 A HK10102676 A HK 10102676A HK 1137756 A1 HK1137756 A1 HK 1137756A1
Authority
HK
Hong Kong
Prior art keywords
hif
prolyl
hydroxylase inhibitors
dihydropyrazolones
substituted
Prior art date
Application number
HK10102676.5A
Other languages
English (en)
Inventor
Kai Thede
Ingo Flamme
Felix Oehme
Jens-Kerim Ergden
Friederike Stoll
Joachim Schuhmacher
Hanno Wild
Peter Kolkhof
Hartmut Beck
Metin Akbaba
Mario Jeske
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of HK1137756A1 publication Critical patent/HK1137756A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
HK10102676.5A 2006-10-26 2010-03-15 取代二氫吡唑啉酮和它們作爲 -脯氨酰- -羥化酶抑制劑的用途 HK1137756A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006050513A DE102006050513A1 (de) 2006-10-26 2006-10-26 Substitiuierte Dihydropyrazolone und ihre Verwendung
PCT/EP2007/008977 WO2008049538A1 (de) 2006-10-26 2007-10-17 Substituierte dihydropyrazolone und ihre verwendung als hif-prolyl-4 -hydroxylase inhibitoren

Publications (1)

Publication Number Publication Date
HK1137756A1 true HK1137756A1 (zh) 2010-08-06

Family

ID=38922682

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10102676.5A HK1137756A1 (zh) 2006-10-26 2010-03-15 取代二氫吡唑啉酮和它們作爲 -脯氨酰- -羥化酶抑制劑的用途

Country Status (10)

Country Link
US (1) US8524699B2 (zh)
EP (1) EP2089380B1 (zh)
JP (1) JP5300729B2 (zh)
KR (1) KR20090069181A (zh)
CN (1) CN101541785B (zh)
CA (1) CA2667392C (zh)
DE (1) DE102006050513A1 (zh)
ES (1) ES2593331T3 (zh)
HK (1) HK1137756A1 (zh)
WO (1) WO2008049538A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008020113A1 (de) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
WO2010093727A1 (en) * 2009-02-10 2010-08-19 Janssen Pharmaceutica Nv Quinazolinones as prolyl hydroxylase inhibitors
US8796263B2 (en) * 2010-08-13 2014-08-05 Janssen Pharmaceutica Nv 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors
WO2012022120A1 (zh) * 2010-08-18 2012-02-23 山东轩竹医药科技有限公司 二氢吡唑类化合物
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
CA2851082A1 (en) * 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
IN2014DN03155A (zh) 2011-10-25 2015-05-22 Janssen Pharmaceutica Nv
CN111825689B (zh) * 2019-04-17 2023-05-05 中国医药研究开发中心有限公司 一种二氢吡唑啉酮类化合物的晶型及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR63123B (en) 1975-12-11 1979-09-11 Lilly Co Eli Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
US4075003A (en) 1975-12-11 1978-02-21 Eli Lilly And Company Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
PL103509B1 (pl) 1976-09-20 1979-06-30 Lilly Co Eli Srodek chwastobojczy
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) * 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE3527157A1 (de) 1985-07-30 1987-02-12 Bayer Ag 1-heteroaryl-4-aryl-pyrazol-derivate
JPS63130593A (ja) * 1986-11-20 1988-06-02 Mitsubishi Kasei Corp ピラゾロン誘導体
JPH0742230B2 (ja) * 1986-11-20 1995-05-10 三菱化学株式会社 過酸化脂質生成抑制剤
FR2725988B1 (fr) 1994-10-24 1997-01-24 Roussel Uclaf Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
DE19909237A1 (de) 1999-03-03 2000-09-07 Merck Patent Gmbh Pyrazol-3-on-derivate
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
JP4316893B2 (ja) 2001-05-16 2009-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｓｒｃおよび他のプロテインキナーゼのインヒビター
WO2003051833A2 (en) 2001-12-18 2003-06-26 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CA2522441A1 (en) 2003-03-27 2004-10-14 Emory University Hif-1 inhibitors
WO2004089303A2 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
WO2004099371A2 (en) 2003-05-01 2004-11-18 Panacea Pharmaceuticals, Inc. Methods of treating ischemic related conditions
WO2005030121A2 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds, compositions and methods
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
AT504818A1 (de) 2004-07-30 2008-08-15 Windtec Consulting Gmbh Triebstrang einer windkraftanlage
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung

Also Published As

Publication number Publication date
CN101541785A (zh) 2009-09-23
US8524699B2 (en) 2013-09-03
DE102006050513A1 (de) 2008-04-30
WO2008049538A1 (de) 2008-05-02
KR20090069181A (ko) 2009-06-29
CA2667392C (en) 2015-05-05
ES2593331T3 (es) 2016-12-07
CN101541785B (zh) 2014-03-12
JP5300729B2 (ja) 2013-09-25
EP2089380B1 (de) 2016-06-29
JP2010507606A (ja) 2010-03-11
EP2089380A1 (de) 2009-08-19
US20120264704A1 (en) 2012-10-18
CA2667392A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
HUS2200052I1 (hu) Imidazotriazinok és imidazopirimidinek mint kinázgátlók
TWI561237B (en) Substituted dihydropyrazolones and their use
HK1137756A1 (zh) 取代二氫吡唑啉酮和它們作爲 -脯氨酰- -羥化酶抑制劑的用途
EP2200977A4 (en) F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
HK1208000A1 (zh) 鋶化合物及其用途
EP2084139A4 (en) OXAZOLIDINIUM COMPOUNDS AND USE AS HYDRATINE HIBITORS
GB0611115D0 (en) Compounds and their use
EP2069371A4 (en) ORGANO ARSENOXIDE COMPOUNDS AND THEIR USE
IL192820A0 (en) Novel compounds and use thereof
GB0619611D0 (en) Compounds and their use
GB0619610D0 (en) Compounds and their use
GB0619609D0 (en) Compounds and their use
GB0608846D0 (en) Compounds and their use
GB0616577D0 (en) Compounds and their use
GB0603378D0 (en) Compounds and their use
GB0610888D0 (en) Compounds and their use
GB0603374D0 (en) Compounds and their use
GB0603376D0 (en) Compounds and their use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181017